British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy

Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the pauci...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoriadou, S, Clubbe, R, Garcez, T, Huissoon, A, Grosse-Kreul, D, Jolles, S, Henderson, K, Edmonds, J, Lowe, D, Bethune, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Editors’ Choice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585546/
https://www.ncbi.nlm.nih.gov/pubmed/35924867
http://dx.doi.org/10.1093/cei/uxac070
Descripción
Sumario:Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.

Ejemplares similares